Targets › FGF21R
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Jul 2028.
Open in Phaseline: the race on FGF21R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Efimosfermin (BOS-580) FGF21 receptor agonist | FGF21R | Phase 2 | Metabolic Dysfunction-Associated Steatohepatitis | Jul 2028 |
Metabolic Dysfunction-Associated Steatohepatitis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.